Editas Medicine doses first pediatric patient in clinical trial for LCA10
April 11th 2022The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.
Read More
Ocugen announces first patient dosed in Phase 1/2 clinical trial for gene therapy candidate OCU400
April 5th 2022According to the company, the modifier gene therapy candidate is for the treatment of retinitis pigmentosa resulting from mutations in the nuclear receptor subfamily 2 group E member 3 and Rhodopsin genes.
Read More
Scientists eye up gene required for survival of an important retinal neuron
March 23rd 2022A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells – a class of neurons located in the retina that are critical for vision.
Read More
Study focuses on potential biologic to treat allergic eye disease
March 18th 2022A team of investigators has found that nomacopan, a recombinant biologic derived from blood-feeding ticks, may be an option for the treatment of allergic eye disease due to its ability to down-regulate the LTB4/C5 pathways in experimental allergy conjunctivitis.
Read More
Intensive multimodal therapy is effective for orbital retinoblastoma
March 17th 2022Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.
Read More
Apellis announces longer-term data from Phase 3 DERBY and OAKS studies for geographic atrophy
March 16th 2022According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.
Read More
AMD: New treatments from intravitreal injections to gene therapy
March 3rd 2022Christina Y. Weng, MD, MBA, an associate professor of ophthalmology and surgical retina fellowship program director at Baylor College of Medicine in Houston, recently shared some standout therapies for macular degeneration.
Read More
CEBF virtual symposium showcases vision research from three Northeast Ohio institutions
February 2nd 2022Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.
Read More
Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt patients
January 25th 2022Nanoscope Therapeutics has received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.
Read More
4D Molecular Therapeutics announces first patient dosed in Phase 1/2 Clinical Trial of 4D-150
January 7th 2022According to the company, 4D-150 is a dual-transgene, intravitreal gene therapy designed to inhibit four distinct angiogenic factors to prevent angiogenesis and reduce vascular permeability for the treatment of wet AMD.
Read More
Adverum Biotechnologies gets Orphan Drug Designation from FDA for gene therapy candidate
January 6th 2022The novel gene therapy product candidate is being developed as a potential single intravitreal administration for blue cone monochromacy by delivering a functional copy of the OPN1LW gene.
Read More